Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Bayer AG buy ROKOBA

Start price
€25.96
08.08.24 / 50%
Target price
-
08.09.24
Performance (%)
11.90%
End price
€29.05
09.09.24
Summary
This prediction ended on 09.09.24 with a price of €29.05. The BUY prediction by ROKOBA finished with a performance of 11.90%. ROKOBA has 50% into this prediction

Bayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.

Performance without dividends (%)
Name 1w 1m 1y
Bayer AG 8.990% 8.990% 83.966%
iShares Core DAX® 0.734% 1.458% 17.980%
iShares Nasdaq 100 -2.686% -0.146% 3.810%
iShares Nikkei 225® -2.261% -2.729% 11.679%
iShares S&P 500 -1.346% 0.467% 1.970%

According to ROKOBA what are the pros and cons of Bayer AG for the foreseeable future?

Pros
Higher EBIT margin than peer group
Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
Fair valuation
positive Cash Flow expected
High dividend yield expected
Revenue growth >5% per year expected
Good rating
Valuable balance sheet
Standard Investments for future growth
ROE higher than 10% per year
Normal challenges to pay loans and raise capital
Capable Management
Good culture
Some uniques
Differentiated customer and product portfolio
Sustainability is important
Stable Large shareholder and/or long term investor
Medium risks for its business
Top 10 in its market
Small cyclical dependencies
Future proof or reliable business model
Well known brand
Cons
Little innovation
Growths slower than the competition

Comments by ROKOBA for this prediction

In the thread Bayer AG diskutieren

Bayer- hat nur noch Luft nach oben. Prozessuale Risiken sind eingedämmt. Kurstechnisch und dividendentechnisch nur eine Richtung wahrscheinlich. Dieses Betrachtung berücksichtigt den Gesamtaktienmarkt und unabhängig der Richtung. Ein sicherer Hafen - die großen Wellen sind draußen. Wenn es unruhig wird will jeder dahin, was dann zusätzlich treiben wird.
Kurzfristig - 29
Mittelfristig- 33-35
Langfristig -41-45 


In the thread Trading Bayer AG
Prediction Buy
Perf. (%) 11.90%
Target price
Change
Ends at 08.09.24

Die von ROKOBA gewählte maximale Laufzeit wurde überschritten